Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
22
ANIX Quote, Financials, Valuation and Earnings
Last price:
$3.18
Seasonality move
:
12.71%
Day range:
$3.18 - $3.41
52-week range:
$2.07 - $5.46
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.35x
Volume:
226.2K
Avg. volume:
416.5K
1-year change:
24.51%
Market cap:
$105.3M
Revenue:
--
EPS (TTM):
-$0.34
Analysts' Opinion
-
Consensus RatingAnixa Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, Anixa Biosciences, Inc. has an estimated upside of 212.5% from its current price of $3.20.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $3.20.
Fair Value
-
According to the consensus of 3 analysts, Anixa Biosciences, Inc. has 212.5% upside to fair value with a price target of $10.00 per share.
ANIX vs. S&P 500
-
Over the past 5 trading days, Anixa Biosciences, Inc. has underperformed the S&P 500 by -2.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Anixa Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Anixa Biosciences, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Anixa Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Anixa Biosciences, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Anixa Biosciences, Inc. reported earnings per share of -$0.07.
Enterprise value:
88.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-2.87x
EV / Free cash flow:
-12.90x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$36K
Return On Assets:
-57.22%
Net Income Margin (TTM):
--
Return On Equity:
-64.77%
Return On Invested Capital:
-63.93%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-07-31 | 2024-07-31 | 2025-07-31 | 2024-07-31 | 2025-07-31 | |
| Income Statement | ||||||
| Revenue | $210K | -- | -- | -- | -- | |
| Gross Profit | $165K | -$40K | -$36K | -$3K | -$9K | |
| Operating Income | -$11.6M | -$13.7M | -$12M | -$3.6M | -$2.4M | |
| EBITDA | -$11.5M | -$13.7M | -$12M | -$3.6M | -$2.4M | |
| Diluted EPS | -$0.34 | -$0.39 | -$0.34 | -$0.10 | -$0.07 | |
| Period Ending | 2021-07-31 | 2022-07-31 | 2023-07-31 | 2024-07-31 | 2025-07-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $37.1M | $32.3M | $26.4M | $22.7M | $17.4M | |
| Total Assets | $37.1M | $32.6M | $26.6M | $22.9M | $17.7M | |
| Current Liabilities | $1.2M | $1.5M | $1.9M | $2M | $2.1M | |
| Total Liabilities | $1.2M | $1.7M | $2M | $2.2M | $2.2M | |
| Total Equity | $35.9M | $30.9M | $24.6M | $20.7M | $15.4M | |
| Total Debt | -- | $187K | $136K | $213K | $174K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-07-31 | 2024-07-31 | 2025-07-31 | 2024-07-31 | 2025-07-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.8M | -$8.4M | -$6.8M | -$2.6M | -$1.5M | |
| Cash From Investing | -$14.9M | $2.8M | $5.1M | $2.7M | -$833K | |
| Cash From Financing | -$297K | $3.6M | $2M | $149K | $1.9M | |
| Free Cash Flow | -$5.8M | -$8.4M | -$6.8M | -$2.6M | -$1.5M | |
ANIX
Sector
Market Cap
$105.3M
$28.2M
Price % of 52-Week High
58.65%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
-2.04%
-1.54%
1-Year Price Total Return
24.51%
-18.1%
Beta (5-Year)
0.488
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.33
200-day SMA
Sell
Level
$3.36
Bollinger Bands (100)
Sell
Level
3.09 - 4.39
Chaikin Money Flow
Sell
Level
-31.5M
20-day SMA
Sell
Level
$4.13
Relative Strength Index (RSI14)
Sell
Level
36.83
ADX Line
Sell
Level
24.08
Williams %R
Buy
Level
-99.1215
50-day SMA
Sell
Level
$4.19
MACD (12, 26)
Sell
Level
-0.30
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
141.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.3379)
Sell
CA Score
(Annual)
Level (-1.0879)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (8.4614)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
Stock Forecast FAQ
In the current month, ANIX has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ANIX average analyst price target in the past 3 months is $10.00.
-
Where Will Anixa Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Anixa Biosciences, Inc. share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About Anixa Biosciences, Inc.?
Analysts are divided on their view about Anixa Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Anixa Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Anixa Biosciences, Inc.'s Price Target?
The price target for Anixa Biosciences, Inc. over the next 1-year time period is forecast to be $10.00 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ANIX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Anixa Biosciences, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ANIX?
You can purchase shares of Anixa Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Anixa Biosciences, Inc. shares.
-
What Is The Anixa Biosciences, Inc. Share Price Today?
Anixa Biosciences, Inc. was last trading at $3.18 per share. This represents the most recent stock quote for Anixa Biosciences, Inc.. Yesterday, Anixa Biosciences, Inc. closed at $3.20 per share.
-
How To Buy Anixa Biosciences, Inc. Stock Online?
In order to purchase Anixa Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ANIX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ANIX
Sector
P/E ratio
--
23.92x
PEG ratio
-2.87x
-0.01x
P/B ratio
6.35x
1.83x
Price / LTM sales
--
1.61x
Growth Metrics
ANIX
Sector
Revenue growth
--
4.6%
Earnings growth
32%
10.88%
Revenue (5-year growth)
-100%
6.46%
Earnings forecast
-$0.09
-$0.21
Profitability
ANIX
Sector
Profitability FY 2024
-$37K
$3.5M
Return on invested capital
-63.93%
-31.84%
Return on assets
-57.22%
-27.96%
Return on equity
-64.77%
-37.63%
Earnings Date
Last Earnings Date
Sep
10
Next Earnings Date
Jan
9
Estimated Next Earnings Date
Dec
10
Balance Sheet
ANIX
Sector
Total cash
$16M
$26.3M
Short term investments
$18.7M
$25.7M
Total assets
$21.6M
$76.9M
Long term debt
$213K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
